SCHEMBL3514243

SCHEMBL3514243

O=C(CO)CC1CCCC1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 3/20 0.45
KMT2A Q03164 2/20 0.45
HPGD P15428 2/20 0.45
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
EPHX2 P34913 1/20 0.37
ALOX5 P09917 2/20 0.37
ADH1B P00325 1/20 0.34
ADH1C P00326 1/20 0.34
ADH1A P07327 1/20 0.34
ADH4 P08319 1/20 0.34
ADH7 P40394 1/20 0.34
SLC1A3 P43003 1/20 0.34
SLC1A2 P43004 1/20 0.34
SLC1A1 P43005 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL502374 0.97 EPHX1 (0.48) EPHX1KMT2AHPGDNPC1RAB9A
SCHEMBL3116167 0.86 EPHX1 (0.50) EPHX1KMT2AHPGDNPC1RAB9A
SCHEMBL7945281 0.83 EPHX1 (0.54) EPHX1KMT2AHPGDNPC1RAB9A
SCHEMBL1148328 0.83 EPHX1 (0.54) EPHX1KMT2AHPGDNPC1RAB9A
SCHEMBL9298439 0.81 EPHX1 (0.52) EPHX1KMT2AHPGDNPC1RAB9A
SCHEMBL3855877 0.80 KMT2A (0.44) EPHX1KMT2AHPGDNPC1RAB9A
SCHEMBL11974545 0.79 EPHX1 (0.56) EPHX1KMT2AHPGDNPC1RAB9A
SCHEMBL24524829 0.78 GABRA5 (0.47) EPHX1EPHX2
SCHEMBL791953 0.78 EPHX1 (0.41) EPHX1KMT2AHPGDEPHX2
SCHEMBL4646102 0.77 KMT2A (0.43) EPHX1KMT2AHPGDNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190146340-A1 RADIATION-SENSITIVE RESIN COMPOSITION AND RESIST PATTERN-FORMING METHOD JSR CORPORATION (JP) 2019-05-16 US disclosed
US-8183275-B2 Substituted imidazoles as bombesin receptor subtype-3 modulators MERCK SHARP & DOHME CORP. (US) 2012-05-22 US disclosed
US-8183275-B2 Substituted imidazoles as bombesin receptor subtype-3 modulators MERCK SHARP & DOHME CORP. (US) 2012-05-22 US disclosed
US-8183275-B2 Substituted imidazoles as bombesin receptor subtype-3 modulators MERCK SHARP & DOHME CORP. (US) 2012-05-22 US disclosed
US-20100204236-A1 Substituted imidazoles as bombesin receptor subtype-3 modulators MERCK SHARP & DOHME CORP. 2010-08-12 US disclosed
US-20100204236-A1 Substituted imidazoles as bombesin receptor subtype-3 modulators MERCK SHARP & DOHME CORP. 2010-08-12 US disclosed
US-20100204236-A1 Substituted imidazoles as bombesin receptor subtype-3 modulators MERCK SHARP & DOHME CORP. 2010-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204236-A1 Substituted imidazoles as bombesin receptor subtype-3 modulators BRS3, GPR119, GIPR EPHX1 4147/4885KMT2A 4157/4885HPGD 4109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.